Evidence map›Paper›PMID 37345752›Full record

ArticleJournal of the American Heart Association2023

Derivation of a Protein Risk Score for Cardiovascular Disease Among a Multiracial and Multiethnic HIV+ Cohort.

Sandra E Safo, Lillian Haine, Jason Baker, Cavan Reilly, Daniel Duprez, James D Neaton, Mamta K Jain, Alejandro Arenas-Pinto, Mark Polizzotto, Therese Staub and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Sandra E SafoUniversity of Minnesota Minneapolis MN USA.ORCID 0000-0001-9593-4778
Lillian HaineUniversity of Minnesota Minneapolis MN USA.ORCID 0000-0003-1483-3794
Jason BakerHennepin County Medical Center Minneapolis MN USA.ORCID 0000-0002-5542-1545
Cavan ReillyUniversity of Minnesota Minneapolis MN USA.
Daniel DuprezUniversity of Minnesota Minneapolis MN USA.ORCID 0000-0002-0993-6839
James D NeatonUniversity of Minnesota Minneapolis MN USA.ORCID 0000-0001-9986-069X
Mamta K JainUniversity of Texas Southwestern Dallas TX USA.ORCID 0000-0003-2292-6544
Alejandro Arenas-PintoMRC Clinical Trials Unit at University College London Institute of Clinical Trials & Methodology London UK.ORCID 0000-0002-3368-5005
Mark PolizzottoAustralian National University Canberra Australia.ORCID 0000-0002-6446-183X
Therese StaubLuxembourg Hospital Center Luxembourg City Luxembourg.
ESPRIT, INSIGHT FIRST, SMART and START study groups
University of Minnesota · USAustralian National University · AUCentre Hospitalier de Luxembourg · LUHennepin County Medical Center · USMRC Clinical Trials Unit at UCL · GBThe University of Texas Southwestern Medical Center · US

Funding

International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)U01AI068641 · NIAID · UNIVERSITY OF MINNESOTA · PI NEATON, JAMES DENNIS · 2006 to 2010
$120.1M
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)UM1AI068641 · NIAID · UNIVERSITY OF MINNESOTA · PI NEATON, JAMES DENNIS · 2011 to 2014
$83.5M
COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ON AIDSU01AI046362 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI GORDIN, FRED M · 2000 to 2006
$75.9M
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT): STARTUM1AI120197 · NIAID · UNIVERSITY OF MINNESOTA · PI NEATON, JAMES DENNIS · 2015 to 2017
$65.1M
INTERNATIONAL PHASE III IL-2 STUDYU01AI046957 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI NEATON, JAMES DENNIS · 1999 to 2005
$56.4M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
TERRY BEIRN COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ONU01AI042170 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI NEATON, JAMES DENNIS · 1997 to 2006
$23.2M
Extended follow-up of randomized participants in the INSIGHT START trialU01AI136780 · NIAID · UNIVERSITY OF MINNESOTA · PI GRUND, BIRGIT, REILLY, CAVAN S. · 2019 to 2024
$18.0M
Institutional Career Development CoreKL2TR002492 · NCATS · UNIVERSITY OF MINNESOTA · PI INGBAR, DAVID H · 2018 to 2022
$6.3M
Training in Biostatistics for Heart, Lung and Blood Disease ResearchT32HL129956 · NHLBI · UNIVERSITY OF MINNESOTA · PI NEATON, JAMES DENNIS · 2016 to 2020
$1.1M
NCATS NIH HHS KL2 TR002492NCATS NIH HHS UL1 TR002494NHLBI NIH HHS T32 HL129956NIAID NIH HHS U01 AI042170NIAID NIH HHS U01 AI046362NIAID NIH HHS U01 AI046957NIAID NIH HHS U01 AI068641NIAID NIH HHS U01 AI136780NIAID NIH HHS UM1 AI068641NIAID NIH HHS UM1 AI120197
6 · The paper itself

Abstract

Background Cardiovascular disease risk prediction models underestimate CVD risk in people living with HIV (PLWH). Our goal is to derive a risk score based on protein biomarkers that could be used to predict CVD in PLWH. Methods and Results In a matched case-control study, we analyzed normalized protein expression data for participants enrolled in 1 of 4 trials conducted by INSIGHT (International Network for Strategic Initiatives in Global HIV Trials). We used dimension reduction, variable selection and resampling methods, and multivariable conditional logistic regression models to determine candidate protein biomarkers and to generate a protein score for predicting CVD in PLWH. We internally validated our findings using bootstrap. A protein score that was derived from 8 proteins (including HGF [hepatocyte growth factor] and interleukin-6) was found to be associated with an increased risk of CVD after adjustment for CVD and HIV factors (odds ratio: 2.17 [95% CI: 1.58-2.99]). The protein score improved CVD prediction when compared with predicting CVD risk using the individual proteins that comprised the protein score. Individuals with a protein score above the median score were 3.10 (95% CI, 1.83-5.41) times more likely to develop CVD than those with a protein score below the median score. Conclusions A panel of blood biomarkers may help identify PLWH at a high risk for developing CVD. If validated, such a score could be used in conjunction with established factors to identify CVD at-risk individuals who might benefit from aggressive risk reduction, ultimately shedding light on CVD pathogenesis in PLWH.

Indexed as

Cardiovascular DiseasesHIV InfectionsBiomarkersCase-Control StudiesHumansRisk FactorsBiomarkerscardiovascular diseaseHIVOlinkprotein biomarkersproteomics

Identifiers

PMID37345752
PMCPMC10356060
OpenAlexW4381598466

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.